Venetoclax, Lenalidomide and Rituximab for Patients with Relapsed or Refractory Mantle Cell Lymphoma - Data from the Nordic Lymphoma Group NLG-MCL7 (VALERIA) Phase I Trial: Stopping Treatment in Molecular Remission Is Feasible

被引：7
|
作者：
Jerkeman, Mats
Kolstad, Arne
Niemann, Carsten Utoft
Groenbaek, Kirsten
Hutchings, Martin
Pasanen, Annika
Ekberg, Sara
Wader, Karin Fahl
Glimelius, Ingrid
机构：
来源：
BLOOD | 2020年 / 136卷
关键词：
D O I：
10.1182/blood-2020-133273
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [21] Idelalisib in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma: First Results from the Nordic Lymphoma Group NLG-LBC-07 (ILIAD) Phase II Trial
    Fjorden, Karin
    Ekberg, Sara
    Kuric, Nevzeta
    Smedby, Karin Ekstroem
    Lagerlof, Ingemar
    Larsen, Thomas S.
    Jorgensen, Judit M.
    Brown, Peter de Nully
    Jerkeman, Mats
    BLOOD, 2020, 136
  • [22] Acalabrutinib and Rituximab in Elderly Patients with Newly Diagnosed Mantle Cell Lymphoma Including a Matched Population-Based External Comparator- the Nordic Lymphoma Group NLG-MCL8 (ALTAMIRA) Phase II Trial
    Jerkeman, Mats
    Wader, Karin Fahl
    Glimelius, Ingrid
    Pasanen, Annika
    Kim, Won Seog
    Hansen, Louise Kruger
    Riise, Jon
    Hutchings, Martin
    Elhussein, Hashim Hussein
    Niemann, Carsten Utoft
    Jorgensen, Rasmus Rask Kragh
    El-Galaly, Tarec Christoffer
    Ehinger, Mats
    Beiske, Klaus
    Amini, Rose-Marie
    Moller, Michael Boe
    Karjalainen-Lindsberg, Marja-Liisa
    Christensen, Jacob Haaber
    BLOOD, 2024, 144 : 747 - 748
  • [23] Lenalidomide, bendamustine, and rituximab as first-line therapy for patients > 65 years with mantle cell lymphoma: The Nordic Lymphoma Group MCL4 (LENA-BERIT) trial
    Jerkeman, M.
    Kolstad, A.
    Laurell, A.
    Raty, R.
    Gnonbaek, K.
    Geisler, C.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [24] Radioimmunotherapy in relapsed/refractory mantle cell lymphoma patients: final results of a European MCL Network Phase II Trial
    S Ferrero
    A Pastore
    C W Scholz
    R Forstpointner
    A Pezzutto
    L Bergmann
    L Trümper
    J Finke
    U Keller
    P Ghione
    R Passera
    W Hiddemann
    O Weigert
    M Unterhalt
    M Dreyling
    Leukemia, 2016, 30 : 984 - 987
  • [25] Phase I trial of fludarabine, bortezomib and rituximab for relapsed and refractory indolent and mantle cell non-Hodgkin lymphoma
    Barr, Paul M.
    Fu, Pingfu
    Lazarus, Hillard M.
    Horvath, Nancy
    Gerson, Stanton L.
    Koc, Omer N.
    Bahlis, Nizar J.
    Snell, Michael R.
    Dowlati, Afshin
    Cooper, Brenda W.
    BRITISH JOURNAL OF HAEMATOLOGY, 2009, 147 (01) : 89 - 96
  • [26] Radioimmunotherapy in relapsed/refractory mantle cell lymphoma patients: final results of a European MCL Network Phase II Trial
    Ferrero, S.
    Pastore, A.
    Scholz, C. W.
    Forstpointner, R.
    Pezzutto, A.
    Bergmann, L.
    Truemper, L.
    Finke, J.
    Keller, U.
    Ghione, P.
    Passera, R.
    Hiddemann, W.
    Weigert, O.
    Unterhalt, M.
    Dreyling, M.
    LEUKEMIA, 2016, 30 (04) : 984 - 987
  • [27] Phase I Safety and Preliminary Efficacy of Acalabrutinib, Venetoclax, and Obinutuzumab (AVO) in Patients with Relapsed/Refractory Mantle Cell Lymphoma
    Kim, Austin I.
    Armand, Philippe
    Redd, Robert A.
    Forsyth, Megan
    Branch, Paul
    Pazienza, Samantha
    Brennan, Lisa
    Patterson, Victoria
    Waisgerber, Susan M.
    Merryman, Reid W.
    Fisher, David C.
    Ryan, Christine E.
    Ahn, Inhye E.
    Crombie, Jennifer L.
    Odejide, Oreofe O.
    LaCasce, Ann
    Jacobson, Caron A.
    Jacobsen, Eric
    Parry, Erin M.
    Davids, Matthew S.
    Brown, Jennifer R.
    Freedman, Arnold S.
    Riedell, Peter A.
    Murakami, Mark Alan
    BLOOD, 2023, 142
  • [28] A phase II trial of bortezomib plus lenalidomide for relapsed/refractory mantle cell lymphoma (MCL) (CALGB 50501): Results of a planned interim analysis
    Morrison, V. A.
    Johnson, J. L.
    Jung, S.
    Leonard, J. P.
    Cheson, B. D.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [29] ORAL LENALIDOMIDE PLUS 4 DOSES OF RITUXIMAB INDUCED PROLONGED REMISSIONS IN RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA: A COMPLETED PHASE I/II CLINICAL TRIAL
    Wang, M.
    Fayad, L.
    Wagner-Bartak, N.
    Hagemeister, F.
    Neelapu, S.
    Fanale, M.
    Younes, A.
    Cabanillas, F.
    Zhang, L.
    Champlin, R.
    Kwak, L.
    Feng, L.
    Bell, N.
    Zeldis, J.
    Romaguera, J.
    ANNALS OF ONCOLOGY, 2011, 22 : 119 - 119
  • [30] Idelalisib in relapsed/refractory diffuse large B-cell lymphoma: results from a Nordic Lymphoma Group phase II trial
    Fjorden, Karin
    Ekberg, Sara
    Kuric, Nevzeta
    Smedby, Karin E.
    Lagerlof, Ingemar
    Larsen, Thomas S.
    Jorgensen, Judit M.
    de Nully Brown, Peter
    Jerkeman, Mats
    BRITISH JOURNAL OF HAEMATOLOGY, 2022, 196 (02) : 437 - 440
12345